In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS

Prognostic role of coronary artery calcium score in patients with metabolic syndrome

Session Poster session II

Speaker Jamol Uzokov

Event : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Coronary Calcium Score
  • Session type : Poster Session

Authors : JK Uzokov (Tashkent,UZ), AL Alyavi (Tashkent,UZ), BA Alyavi (Tashkent,UZ), NU Kayumov (Tashkent,UZ)

JK Uzokov1 , AL Alyavi1 , BA Alyavi2 , NU Kayumov2 , 1Republican Specialized Scientific-Practical Medical Center Therapy and Medical Rehabilitation - Tashkent - Uzbekistan , 2Tashkent Pediatric Medical Institute - Tashkent - Uzbekistan ,


Background: Metabolic syndrome (MetS) is characterized by constellation of several risk factors such as hypertension, abdominal obesity, dyslipidemia, insulin resistance and glucose intolerance and considered risk for the development of the future cardiovascular disease and diabetes mellitus. Aim of the present study was to evaluate coronary artery calcium score (CACS) detected by multi slice computed tomography (MSCT) for the development of future cardiovascular disease (CVD).

Methods: 112 consecutive metabolic syndrome patients without history of cardiovascular disease and 56 healthy subjects were enrolled in this study. Multi slice computed tomography was conducted to estimate CACS and all patients were followed-up during the mean 48±12.6 months. All laboratory and instrumental measurements were performed at baseline and during the follow up period. Statistical analysis were done by using STATA software.

Results: Compared with controls, patients with metabolic syndrome had a higher degree of CACS (85.2±78.5 vs. 7.2±12.0, P<0.05). During the mean follow-up period in 15 patients CVD have occurred in patients with metabolic syndrome and in 1 patients in control group. Higher CVD have been occurred in patients with CACS 1-10 (6.0%), 10-100 (50.0%), >100 (44.0%). Among components of the MetS - high LDL Cholesterol (HR 11.0, CI 95% 5.50-18.24, P<0.05), abdominal obesity (HR 2.6, CI 95% 1.12-2.90, P<0.05), hypertension (HR 4.2, CI 95% 2.0-6.8, P<0.05) are predictors of future CVD. As well as, cox regression analysis has revealed that CACS>100 (HR 12.4, CI 95% 5.65-22.70, P<0.05) is a predictor of future CVD.

Conclusion: This study demonstrate that CACS detected by MSCT is a useful method for the prognosis of future CVD in patients with MetS.

This content is currently on FREE ACCESS

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are